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Abstract
Idiopathic pulmonary fibrosis is a peripheral subpleural interstitial lung disorder limited to the lung not involving the 
airways. It has a poor prognosis (survival less than 5 years) and commonly an interstitial pneumonia radiological pattern. 
Patients complain of a chronic dry cough in 80% of cases. A cough is often the first symptom of this rare disease, preceding 
dyspnea by years, and is associated with a poor prognosis, high dyspnea scores and low FVC percentages. The pathogenetic 
mechanisms leading to coughing in IPF are unclear. This review focuses on recent evidence of cough pathophysiology in 
this disease. Gastroesophageal reflux may promote coughing in IPF patients; bile salts and pepsin may be abundant in BAL 
of these patients, inducing overproduction of TGF-β by airway epithelial cells and mesenchymal transition with fibroblast 
recruitment/activation and extracellular matrix deposition. Patients have an enhanced cough reflex to capsaicin and sub-
stance P with respect to control subjects. Moreover, patients with the MUC5B polymorphism show more severe coughing 
as MUC5B encodes for the dominant mucin in the honeycomb cysts of IPF patients. Comorbidities, including asthma, gas-
troesophageal reflux, hypersensitivity pneumonitis, bronchiectasis, chronic obstructive pulmonary disease and emphysema, 
can induce coughing in IPF patients. There is no clear explanation of the causes of coughing in IPF. Further research into the 
pathophysiology of IPF and the pathogenetic mechanisms of coughing is necessary to improve survival and quality of life.
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Abbreviations
IPF  Idiopathic pulmonary fibrosis
ILD  Interstitial lung diseases
HRCT  High resolution computed tomography
BAL  Bronchoalveolar lavage
GER  Gatroesophageal reflux
NSIP  Non specific interstitial pneumonia
FVC  Forced vital capacity
TGF-β  Tumour growth factor
UIP  Usual interstitial pneumonia
GPCR  G-Protein coupled receptor
Introduction
Idiopathic pulmonary fibrosis (IPF) is an interstitial lung dis-
order limited to the lung and associated with poor prognosis 
(mean survival less than 5 years) and commonly an inter-
stitial pneumonia (UIP) radiological pattern. Late diagnosis 
of IPF is common because the signs and symptoms of this 
disease are nonspecific. Eighty percent of patients complain 
of a chronic dry cough, but the prevalence of coughing in 
IPF has not been clearly established due to different defini-
tions and assessment methods [1]. Coughing is often the first 
symptom of this interstitial lung disease, preceding dyspnea 
by years [2–5]. It is an independent marker of disease sever-
ity, being associated with a poor prognosis, high dyspnea 
scores, low FVC percentages, and high rates of exertion 
desaturation [1]. Coughing is more common in IPF patients 
who have never smoked than in smokers [50]. All ages and 
both genders are equally affected. The cough is dry, severe, 
diurnal, induced, for example, by speaking (favoured by 
vibration or mechanical stimulation of nerve receptors) and 
refractory to pharmacological therapies [1, 5]. It can affect 
quality of life by limiting exercise tolerance and determining 
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social health problems [4–7]. Coughing related to IPF may 
be associated with coughing induced by comorbidities such 
as asthma, gastroesophageal reflux (GER) disease, upper 
airway cough syndrome and medications [5].
New approved therapies for IPF have only been partially 
assessed for coughing, although there is growing interest in 
the topic. There is no specific approved therapy for cough-
ing in IPF. Only one trial with thalidomide in a limited 
population of IPF patients with refractory coughing has 
been published [8]. Our research group recently conducted 
a randomised, double blind, placebo-controlled trial on the 
effectiveness of aerosolised carcainium chloride (VRP700) 
in controlling coughing in patients with interstitial lung dis-
eases (ILD) [9]. Nebulised VRP700 therapy improves cough 
and quality of life in hospitalised ILD patients, and is with-
out any significant side effects. In a multicentre trial, Birring 
et al. recently evaluate the efficacy of a new formulation of 
inhaled sodium cromoglycate in the treatment of chronic 
coughing in IPF patients [10].
There is no clear explanation of the causes of coughing 
in IPF patients, especially those never exposed to cigarette 
smoking. The pathogenetic mechanisms of coughing in IPF 
are unclear. Here we review recent evidence concerning the 
pathophysiology of coughing in this disease.
Gastroesophageal reflux
Bile salts and pepsin may be abundant in bronchoalveolar 
lavage (BAL) fluid from IPF patients, inducing overproduc-
tion of TGF-β by airway epithelial cells and mesenchymal 
transition with fibroblast recruitment/activation and extra-
cellular matrix deposition [11–14]. The development of IPF 
seems to be facilitated by recurrent lung insult due to micro-
aspiration of Helicobacter pylori from gastric juice as a con-
sequence of GER [14–18]. Gastroesophageal reflux (GER) 
is common in IPF patients, while in the general population, 
the prevalence of GER disease exceeds that of IPF and only 
a small proportion of subjects with GER develops IPF [11]. 
Non-acid reflux seems to influence coughing in IPF more 
than acid reflux. Pharmacological therapy with pump inhibi-
tors does not improve cough symptoms. Therapy with pro-
ton pump inhibitors is able to increase non-acid reflux [11], 
and some interesting research articles suggest that the most 
apt strategy to treat gastroesophageal reflux in patients with 
IPF should target acid and non-acid reflux [4]. Prokinetic 
therapies, rather than acid suppression therapy alone, may 
be proposed as relevant potential targets of treatment [4].
In IPF, the cough itself may promote GER through an 
increase in trans-diaphragm pressure; concomitant pulmo-
nary fibrosis causes traction of neighbouring structures, 
weakening the lower esophageal sphincter and aggravat-
ing gastric reflux [4, 18]. The surgical approach to GER 
in IPF patients does not yield a significant improvement in 
cough symptoms [19, 20]. Controversial findings have been 
reported on the potential role of GER in IPF pathogenesis. 
Some authors fail to confirm the increased pepsin concen-
trations reported in BAL and exhaled breath condensate 
from IPF patients, suggesting that these findings may not be 
reproducible [19]. Some research groups find higher DLCO 
percentages in patients with IPF and GER than in those with 
no reflux [15].
Architectural distortion of the lungs
In obstructive lung disorders, coughing is generally due to 
airway involvement, but since IPF is not an airway disease, 
the reason for coughing in this peripheral ILD is unclear 
[21]. Idiopathic pulmonary fibrosis causes architectural dis-
tortion and traction bronchiectasis; mechanical forces acti-
vate rapidly adapting receptors in small airways, stimulating 
coughing [22, 23].
The airway traction occurring in IPF may promote the 
development of a cough, particularly in the advanced phase 
of the disease. There is progressive loss of alveolar integrity, 
recruitment/activation of myofibroblasts and excessive col-
lagen deposition damage parenchymal architecture, causing 
airway distortion [22, 23].
Lung fibrosis can destroy the nerves involved in cough 
inhibition, facilitating the symptom. In 2011, Jones et al. 
demonstrated that percussive stimuli to the respiratory tract 
induce coughing in IPF patients, but not in controls, and that 
the cough increases when the base of the lungs (where IPF 
arises) is stimulated. Transmission of vibration caused by 
talking, or even coughing itself, may increase mechanical 
stimulation of sensory receptors, perpetuating the vicious 
circle of IPF and coughing [22].
Increased cough reflex sensitivity
Idiopathic pulmonary fibrosis patients have an enhanced 
cough reflex response to capsaicin and substance P with 
respect to controls, irrespective of the entity of fibrosis 
and GER [24]. The urge to cough, induced by inhalation 
of capsaicin, activates many areas of the cerebral cortex, 
especially in IPF patients (Fig. 1). Stimulation of chemi-
cal cough receptors may be related to subclinical inflam-
mation. Eosinophils and other inflammatory markers have 
been found elevated in BAL fluid of IPF patients [25–28]. 
These mediators may modulate the cough reflex by increas-
ing the presence of G protein coupled receptor (GPCR) and 
substance P in human airway nerves. C-fibre sensory nerves 
seem to be involved in cough development, and it is possible 
to reduce the dry cough associated with IPF by reducing 
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C-fibre nerve activity through a specific receptor [30–34, 
50].
Neurotrophins may be generated in the lungs of IPF 
patients from bronchial and alveolar epithelial cells, mesen-
chymal cells, lymphocytes and macrophages [29, 35]. Neu-
rotrophins regulate different subgroups of sensory neurons, 
increasing capsaicin sensitivity. Interestingly, immunoblots 
have revealed neurotrophin overexpression in patients with 
an UIP, but not a NSIP radiological pattern, although possi-
ble differences between cough impact in IPF and NSIP have 
never been evaluated [36]. Substance P-like immunoreactive 
material has been found overexpressed in BAL and sputum 
from IPF patients with respect to healthy individuals, modu-
lating nerve proliferation and neuroplasticity. Neuropeptides, 
substance P and neurokinin A can stimulate human lung 
fibroblast proliferation and chemotaxis that regulate the 
cough reflex [36].
Genetic factors
Cough is an independent predictor of disease progression. 
It is more severe in IPF patients with MUC5B polymor-
phism [37]. MUC5B encodes an airway mucin that is the 
dominant mucin in the honeycomb cysts of IPF patients [38]. 
Changes in mucin production and clearance aggravate the 
cough [39–41]. Although IPF is commonly associated with 
a dry cough, some patients have a chesty productive cough 
from onset of the disease. In a recent study, the histology of 
autopsy lungs of IPF patients was compared in relation to 
wet and dry cough [42]. IPF patients with hypersecretion 
show mucus gland hypertrophy, accumulation of mucus in 
the airways and mucus hypersecretion [42].
Inflammation
An elevated percentage of polymorphonuclear cells and mast 
cells producing an abundance of cytokines and chemokines 
have been demonstrated in BAL fluid of IPF patients [27, 
28]. Among the inflammatory cells overexpressed in BAL 
and sputum of IPF patients, eosinophils and mast cells are 
involved in fibrosis and cough development. These cells have 
been isolated near fibroblastic foci, and produce histamine, 
tryptase, serotonin and substance P that activate sensory 
nerve C fibres, promoting coughing [30, 31].
Comorbidities
Many years ago, Madison et al. reported that coughing can 
be an expression of different concomitant diseases in more 
than 50% of IPF patients [5]. In particular, the authors sug-
gest that comorbidities that induce coughing in these patients 
include: obstructive sleep apnea (OSA) syndrome, asthma, 
GER, hypersensitivity pneumonitis, bronchiectasis, chronic 
obstructive pulmonary disease and emphysema [5].
Sleep apnea is a possible comorbidity in patients with 
IPF, and its treatment can improve gastroesophageal reflux, 
chronic cough and fibrotic lung damage [43, 44] (Table 1). 
In fact, it has been demonstrated that the intermittent 
hypoxemia of patients with OSA may promote profibrotic 
Fig. 1  Pathogenetic mecha-
nisms of cough in idiopathic 
pulmonary fibrosis (IPF)
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mechanisms, and that obstruction of the upper airways typi-
cal of OSA syndrome may increase trans-diaphragm pres-
sure differences, promoting GER and coughing (Fig. 1) 
[43–46].
The potential role of airway basal cells
Another intriguing aspect is the potential role of airway 
basal cells in IPF pathogenesis and cough development. 
Chilosi and coauthors report an aberrant bronchiolization 
in IPF lung with ∆NP63 expressing cells [47, 48]. IPF 
animal models reveal that airway basal cells may have a 
potential role in the early response to fibrosis, and bron-
choalveolar subpopulations of ABCs are abundantly present 
in fibrotic lesions [49]. Migration and proliferation of a CK 
5/6 + ∆NP63 + progenitor cell population is an early and 
key event in the evolution of pulmonary fibrosis [47]. IPF 
is characterized by fibroblast foci, honeycomb cyst forma-
tion and bronchiolization of the alveolar space [47]. In the 
current model of disease pathogenesis, the bronchiolization 
and honeycomb cysts formation occur after the formation 
of myofibroblast foci. ABCs are recruited potentially in 
response to alveolar epithelial cell injury, and their prolif-
eration and invasion determine the distortion of the alveo-
lar structure that we typically associate with IPF and cough 
[47–50]. A very recent genetic manuscript reports an unex-
pected finding: genes from ABCs are highly enriched in the 
BAL of IPF patients likely to progress, and may suggest an 
unexpected role of ABCs in the pathogenesis of IPF and 
cough [49]. It was demonstrated for the first time that IPF 
might be regarded as a fibrotic lung disease involving and 
originating by the airways basal cells [49].
Conclusion
There is no clear explanation of the possible causes of 
coughing in IPF, a peripheral subpleural disorder not involv-
ing the airways. Further research into the pathophysiology of 
IPF and the pathogenetic mechanisms of coughing is neces-
sary to improve survival and quality of life of patients.
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